MX2019013561A - Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. - Google Patents

Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.

Info

Publication number
MX2019013561A
MX2019013561A MX2019013561A MX2019013561A MX2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A MX 2019013561 A MX2019013561 A MX 2019013561A
Authority
MX
Mexico
Prior art keywords
sup
pyrrolopyridine
treatment
compounds
aniline compounds
Prior art date
Application number
MX2019013561A
Other languages
English (en)
Inventor
John Kincaid
Matthew Duncton
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of MX2019013561A publication Critical patent/MX2019013561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se proporcionan en la presente compuestos, composiciones farmacéuticas que comprenden los compuestos, métodos para preparar los compuestos y métodos de uso de los compuestos y composiciones en el tratamiento de enfermedades y trastornos en un sujeto donde el sujeto necesita de un inhibidor de MEK donde el Compuesto es de acuerdo con la Fórmula (I): (ver fórmula) donde X1, R1, R2, R2a, R3, R3a y R3b son como se describe en la presente.
MX2019013561A 2017-05-19 2018-05-18 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. MX2019013561A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19
US201862663202P 2018-04-26 2018-04-26
PCT/US2018/033547 WO2018213810A1 (en) 2017-05-19 2018-05-18 Pyrrolopyridine-aniline compounds for treatment of dermal disorders

Publications (1)

Publication Number Publication Date
MX2019013561A true MX2019013561A (es) 2022-02-09

Family

ID=62620966

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013561A MX2019013561A (es) 2017-05-19 2018-05-18 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2022001697A MX2022001697A (es) 2017-05-19 2019-11-13 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001697A MX2022001697A (es) 2017-05-19 2019-11-13 Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.

Country Status (11)

Country Link
US (2) US11161845B2 (es)
EP (1) EP3624796A1 (es)
JP (1) JP7212956B2 (es)
KR (1) KR102642411B1 (es)
CN (1) CN111065393B (es)
AU (1) AU2018270295B2 (es)
CA (1) CA3063536A1 (es)
IL (1) IL270752B (es)
MA (1) MA49141A (es)
MX (2) MX2019013561A (es)
WO (1) WO2018213810A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3624795B1 (en) 2017-05-19 2022-04-20 NFlection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
EP4233865A3 (en) * 2018-11-20 2023-09-27 NFlection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
MA55148A (fr) * 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
CA3120371A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
EP4216952A1 (en) * 2020-09-24 2023-08-02 NFlection Therapeutics, Inc. Treatment of cognitive dysfunction with pyrrolopyridine-aniline compounds
CN117157065A (zh) * 2021-01-21 2023-12-01 恩福莱克逊治疗有限公司 吡咯并吡啶-苯胺化合物的晶型
CA3205523A1 (en) * 2021-01-21 2022-07-28 Michael Houghton Processes for preparing pyrrolopyridine-aniline compounds
WO2023096935A1 (en) * 2021-11-23 2023-06-01 Nflection Therapeutics, Inc. Formulations of pyrrolopyridine-aniline compounds
WO2023178269A1 (en) * 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of cutaneous neurofibromas with mirdametinib

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
US8211875B2 (en) 2005-02-02 2012-07-03 Nexgenix Pharmaceuticals Inc Local treatment of neurofibromas
EP2395004B1 (en) 2005-06-22 2016-01-20 Plexxikon Inc. Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
US7893085B2 (en) 2006-08-21 2011-02-22 Genentech, Inc Aza-benzothiophenyl compounds and methods of use
ATE531720T1 (de) 2006-08-21 2011-11-15 Genentech Inc Aza-benzofuranylverbindungen und anwendungsverfahren dafür
JP2010508307A (ja) 2006-10-31 2010-03-18 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
JP5211063B2 (ja) * 2006-11-30 2013-06-12 ジェネンテック， インコーポレイテッド アザ−インドリル化合物及び使用方法
WO2008148034A1 (en) 2007-05-25 2008-12-04 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
AU2008340247B2 (en) 2007-12-21 2012-11-15 Genentech, Inc. Azaindolizines and methods of use
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2012040636A2 (en) 2010-09-24 2012-03-29 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途

Also Published As

Publication number Publication date
AU2018270295B2 (en) 2022-03-03
CA3063536A1 (en) 2018-11-22
IL270752A (en) 2020-01-30
JP2020520995A (ja) 2020-07-16
AU2018270295A1 (en) 2019-12-05
JP7212956B2 (ja) 2023-01-26
IL270752B (en) 2022-06-01
MX2022001697A (es) 2022-04-07
US11161845B2 (en) 2021-11-02
MA49141A (fr) 2020-03-25
CN111065393A (zh) 2020-04-24
EP3624796A1 (en) 2020-03-25
KR102642411B1 (ko) 2024-02-28
CN111065393B (zh) 2023-08-18
US20220033399A1 (en) 2022-02-03
US20200165243A1 (en) 2020-05-28
WO2018213810A1 (en) 2018-11-22
KR20200013239A (ko) 2020-02-06

Similar Documents

Publication Publication Date Title
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2020014098A (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington.
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
MX2020014315A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MX2019014514A (es) Compuestos para tratar la enfermedad de huntington.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MX2021000148A (es) Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2020000404A (es) Inhibidores de tirosina quinasa de bazo (syk).
MX368781B (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
NZ726366A (en) Syk inhibitors
MX2021004582A (es) Compuesto 2-azabiciclo hexano inhibidor de jak.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
AU2018253590A1 (en) Imidazopyridazine compounds
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.